deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT03148327

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer

Sponsor: AstraZeneca

Conditions Carcinoma, Non-Small-Cell Lung
Interventions Durvalumab (MEDI 4736) Radiotherapy
Updated 17 times since 2017 Last updated: Jul 11, 2025 Started: Oct 11, 2017 Primary completion: Jun 1, 2026 Completion: Jun 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 17 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2017 – ~Nov 2017 · 5 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Aug 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Dec 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Nov 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jun 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Jonsson Comprehensive Cancer Center
Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations